Physician profile
Archie W Wright
NPI 1639270440
$5,574.55
in general payments reported to CMS, 2019-2025
55 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.28 · 2020: $131 · 2021: $216 · 2022: $596 · 2023: $1,136 · 2024: $1,648 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,504 · Education: $87.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,503.90 |
| Education | $87.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $518.80 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $460.77 | 2019-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $421.80 | 2023-2025 | Opdivo, Krazati, Opdualag |
| Pfizer INC. | $360.51 | 2020-2025 | |
| Daiichi Sankyo INC. | $352.23 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Lilly USA, LLC | $258.52 | 2022-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals Lp | $254.35 | 2019-2025 | Imfinzi, Enhertu |
| Abbvie INC. | $204.11 | 2023-2025 | Venclexta |
| Seagen INC. | $182.54 | 2022-2023 | Padcev, Adcetris |
| Novartis Pharmaceuticals Corporation | $173.45 | 2023-2025 | |
| Glaxosmithkline, LLC. | $141.78 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Pharmacosmos Therapeutics INC. | $136.46 | 2025 | Cosela, Monoferric |
| Genzyme Corporation | $128.63 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2025 | |
| Eisai INC. | $118.19 | 2021-2024 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $112.04 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Foundation Medicine, INC. | $110.65 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $107.71 | 2021-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $84.95 | 2022-2024 | |
| Beigene USA, INC. | $82.19 | 2023-2025 | Brukinsa, Tevimbra |
| Celgene Corporation | $81.23 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Tersera Therapeutics LLC | $74.39 | 2023-2025 | Zoladex |
| Genmab U.S., INC. | $67.57 | 2024-2025 | Epkinly |
| Genentech USA, INC. | $61.18 | 2023-2025 | Venclexta, Perjeta, Phesgo |
| Kyowa Kirin, INC. | $59.44 | 2024-2025 | Poteligeo |
| Exelixis INC. | $56.42 | 2021-2025 | Cabometyx |
| Gilead Sciences, INC. | $50.20 | 2021-2023 | Trodelvy |
| Amgen INC. | $50.15 | 2021-2022 | |
| Tempus Ai, INC | $46.57 | 2024-2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $41.98 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.99 | 2025 | |
| Janssen Pharmaceuticals, INC | $38.23 | 2022-2024 | |
| Mirati Therapeutics, INC. | $35.83 | 2023-2024 | Krazati |
| Taiho Oncology, INC. | $33.19 | 2023-2024 | |
| Stemline Therapeutics INC. | $33.06 | 2023 | Orserdu |
| Coherus Oncology, INC. | $32.18 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.07 | 2022-2023 | Ninlaro |
| Kite Pharma, INC. | $31.13 | 2022-2023 | Yescarta |
| Springworks Therapeutics, INC. | $30.56 | 2024 | Ogsiveo |
| Morphosys, US INC. | $30.53 | 2021-2023 | Monjuvi |
| Regeneron Healthcare Solutions, INC. | $30.08 | 2023 | Libtayo |
| Agios Pharmaceuticals, INC. | $28.02 | 2023-2024 | Pyrukynd |
| Sobi, INC | $24.24 | 2025 | |
| Karyopharm Therapeutics INC. | $22.77 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $22.22 | 2023 | |
| Legend Biotech USA INC. | $21.93 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.25 | 2024 | Ultomiris |
| Emd Serono, INC. | $19.98 | 2025 | |
| Array Biopharma INC | $19.66 | 2025 | Mektovi, Tukysa, Braftovi |
| Astellas Pharma US INC | $19.35 | 2025 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2023 | |
| Deciphera Pharmaceuticals INC. | $18.06 | 2023 | Qinlock |
| Geron Corporation | $17.40 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $16.86 | 2025 | |
| Cti Biopharma Corp. | $15.57 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archie Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.